Does NICE’s “severity modifier” for assessing diseases need to change?

Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in England and Wales after negotiations collapsed over pricing. <b>Jacqui Wise</b> examines calls for NICE to rethink its weighting system for evaluating new treatments

Authors

Publication Details

Journal
BMJ
Published
2024-11-22
DOI
https://doi.org/10.1136/bmj.q2620
Citations
1
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Does NICE’s “severity modifier” for assessing diseases need to change?

Jacqui Wise
1 citations
BMJ
Advanced Breast Cancer Therapies
0.42
article

Does NICE’s “severity modifier” for assessing diseases need to change?

Jacqui Wise
article en
1 citations

Abstract

Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in England and Wales after negotiations collapsed over pricing. <b>Jacqui Wise</b> examines calls for NICE to rethink its weighting system for evaluating new treatments

BMJVol. 387
Openalex Percentile: Top 30%
Advanced Breast Cancer Therapies
0.42
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Does NICE’s “severity modifier” for assessing diseases need to change? — Jacqui Wise · BMJ (2024) | TGRS Research Map | TGRS